Seung Jin Kim

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers

Tomonori Tanei, Koji Morimoto, Kenzo Shimazu et al. · Clinical Cancer Research · 2009 · 563 citations

Medicine, Oncology, Pharmacology +9

Prediction of Docetaxel Response in Human Breast Cancer by Gene Expression Profiling

Kyoko Iwao‐Koizumi, Ryo Matoba, Noriko Ueno et al. · Journal of Clinical Oncology · 2005 · 313 citations

Life Sciences, Oncology, Pharmacology +16

Stem cell marker aldehyde dehydrogenase 1‐positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression

Koji Morimoto, Seung Jin Kim, Tomonori Tanei et al. · Cancer Science · 2009 · 224 citations · Full text

Medicine, Cancer Biology, Oncology +16

High Thioredoxin Expression Is Associated with Resistance to Docetaxel in Primary Breast Cancer

Seung Jin Kim, Yasuo Miyoshi, Tetsuya Taguchi et al. · Clinical Cancer Research · 2005 · 186 citations · Full text

Medicine, Oncology, Pharmacology +11